Immune Response Evolution in Peanut Epicutaneous Immunotherapy for Peanut-Allergic Children.

Marie BastinWarner W CarrCarla M DavisDavid M FleischerJay A LiebermanSyed Shahzad MustafaThibault HelleputteTimothée BoisDianne E CampbellTodd D GreenMatthew J Greenhawt

Published in: Allergy (2023)

Peanut sIgG4 rise most clearly differentiated Viaskin Peanut versus placebo subjects. sIgG4/sIgE ratios >20.1 and the combination of Ara h 1 and peanut sIgG4/sIgE had moderate ability to predict treatment response and could potentially be useful for clinical monitoring. Additional data are needed to confirm these relationships.

Keyphrases

immune response
young adults
randomized controlled trial
clinical trial
machine learning
high intensity
dendritic cells
toll like receptor